» Articles » PMID: 21107131

Glibenclamide Reduces Hippocampal Injury and Preserves Rapid Spatial Learning in a Model of Traumatic Brain Injury

Overview
Specialties Neurology
Pathology
Date 2010 Nov 26
PMID 21107131
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

Cognitive disturbances after traumatic brain injury (TBI) are frequent, even when neuroimaging shows no overt hemorrhagic or other abnormality. Sulfonylurea receptor 1 (SUR1) plays a key role in various forms of CNS injury, but its role in hippocampal dysfunction after mild to moderate TBI is unknown. To assess the hypothesis that postinjury SUR1 upregulation in the hippocampus is associated with a later disturbance in learning, we studied a rat model of cortical impact TBI calibrated to avoid primary and secondary hemorrhage in the underlying hippocampus. The transcription factor, specificity protein 1, which regulates expression of SUR1 and caspase-3, was activated in the hippocampus 15 minutes after injury. Upregulation of SUR1 protein and of Abcc8 (which encodes SUR1) messenger RNA was evident by 6 hours. To assess the role of SUR1, injured rats were administered vehicle or a low dose of the specific sulfonylurea inhibitor glibenclamide for 1 week. At 2 weeks, the increase in activated caspase-3 in the hilus of glibenclamide-treated rats was half of that in vehicle-treated rats. Testing for rapid learning in a Morris water maze at 4 weeks showed significantly better performance in glibenclamide-treated rats; performance inversely correlated with Fluoro-Jade staining for degenerated neurons in the hilus. We conclude that glibenclamide may have long-term protective effects on the hippocampus after mild-to-moderate TBI.

Citing Articles

Research progress on pleiotropic neuroprotective drugs for traumatic brain injury.

Zhao Q, Li H, Li H, Zhang J Front Pharmacol. 2023; 14:1185533.

PMID: 37475717 PMC: 10354289. DOI: 10.3389/fphar.2023.1185533.


Glibenclamide for Brain Contusions: Contextualizing a Promising Clinical Trial Design that Leverages an Imaging-Based TBI Endotype.

Jha R, Simard J Neurotherapeutics. 2023; 20(6):1472-1481.

PMID: 37306928 PMC: 10684438. DOI: 10.1007/s13311-023-01389-x.


Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage Receiving Sulfonylureas: A Propensity-Adjusted Analysis.

Catapano J, Koester S, Bond K, Srinivasan V, Farhadi D, Rumalla K World Neurosurg. 2023; 176:e400-e407.

PMID: 37236313 PMC: 11578856. DOI: 10.1016/j.wneu.2023.05.073.


Edema after CNS Trauma: A Focus on Spinal Cord Injury.

Seblani M, Decherchi P, Brezun J Int J Mol Sci. 2023; 24(8).

PMID: 37108324 PMC: 10138956. DOI: 10.3390/ijms24087159.


New insights toward molecular and nanotechnological approaches to antidiabetic agents for Alzheimer's disease.

Pradhan S, Sahu P, Behera A Mol Cell Biochem. 2023; 478(12):2739-2762.

PMID: 36949264 DOI: 10.1007/s11010-023-04696-1.